Psyence Biomed Advances Psilocybin Mental Health Treatments
Company Announcements

Psyence Biomed Advances Psilocybin Mental Health Treatments

Story Highlights

Psyence Group (TSE:PSYG) has released an update.

Psyence Group’s associate company, Psyence Biomed, is making significant strides in the field of mental health treatment with nature-derived psilocybin. They have initiated a Phase IIb study for Adjustment Disorder in Palliative Care, expanded their pipeline to include treatments for Substance Use Disorders, and announced a potential acquisition that could lead to the development of synthetic psilocybin-based therapies. These developments, coupled with secured funding, poise Psyence Biomed for pivotal Phase III trials and commercialization.

For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Sells Stake to Psyence Biomedical
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Expands Psilocybin Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Enhances Liquidity with Equity Swap
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App